Creative Medical Technology Holdings, Inc. announced an expanded agreement with Greenstone Biosciences Inc. to integrate Artificial Intelligence (AI) into its human induced pluripotent stem cell (iPSC) platform for diabetes treatment. This collaboration builds on previous progress with Creative Medical’s proprietary hypoimmune iPSC technology, including iPSC-derived pancreatic islet cells currently used in clinical trials.
The partnership aims to leverage AI-driven drug discovery to identify small molecules that enhance insulin secretion, thereby refining the therapeutic potential of the company’s hypoimmunogenic iPSC-derived pancreatic islet cells. Additionally, the program will implement multi-gene editing to develop next-generation hypoimmune iPSC lines with enhanced stealth, survival, and differentiation capabilities. These advancements are designed to optimize pancreatic islet cell function and expand the platform’s applications.
Management estimates that this AI-driven program will reduce R&D time by approximately 50% compared to other methods and generate millions of dollars in cost savings. This strategic integration of AI and genetic engineering is intended to overcome challenges in stem cell-based therapies, such as the need for immunosuppression, paving the way for safer and more effective cell-based treatments for diabetes and other chronic conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.